Tempus AI SEC Filings

Type
Report
Date
SCHEDULE 13GSCHEDULE 13G-Formular3/6/2026
4Insidertransaktion3/4/2026
4Insidertransaktion3/4/2026
144144-Formular3/2/2026
144144-Formular3/2/2026
33-Formular2/25/2026
S-8S-8-Formular2/24/2026
10-KJahresbericht2/24/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/24/2026
4Insidertransaktion2/20/2026
4Insidertransaktion2/20/2026
4Insidertransaktion2/20/2026
4Insidertransaktion2/20/2026
4Insidertransaktion2/20/2026
4Insidertransaktion2/20/2026
144144-Formular2/20/2026
144144-Formular2/20/2026
144144-Formular2/19/2026
144144-Formular2/19/2026
144144-Formular2/19/2026
144144-Formular2/19/2026
144144-Formular2/19/2026
144144-Formular2/19/2026
144144-Formular2/19/2026
144144-Formular2/19/2026
4Insidertransaktion2/13/2026
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/10/2026
4Insidertransaktion2/4/2026
4Insidertransaktion1/30/2026
144144-Formular1/28/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/12/2026
4Insidertransaktion1/7/2026
4Insidertransaktion1/6/2026
4Insidertransaktion12/22/2025
144144-Formular12/18/2025
4Insidertransaktion12/18/2025
144144-Formular12/16/2025
4Insidertransaktion12/12/2025
144144-Formular12/11/2025
4Insidertransaktion12/9/2025
144144-Formular12/5/2025
4Insidertransaktion12/3/2025
4Insidertransaktion12/3/2025
4Insidertransaktion12/3/2025
4Insidertransaktion11/28/2025
4Insidertransaktion11/25/2025
4Insidertransaktion11/25/2025
144144-Formular11/24/2025
144144-Formular11/24/2025
4Insidertransaktion11/20/2025
4Insidertransaktion11/20/2025
144144-Formular11/20/2025
4Insidertransaktion11/20/2025
4Insidertransaktion11/20/2025
4Insidertransaktion11/20/2025
4Insidertransaktion11/20/2025
144144-Formular11/19/2025
144144-Formular11/18/2025
144144-Formular11/18/2025
144144-Formular11/18/2025
144144-Formular11/18/2025
144144-Formular11/18/2025
144144-Formular11/18/2025
4Insidertransaktion11/13/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular11/13/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular11/12/2025
144144-Formular11/12/2025
4Insidertransaktion11/5/2025
4Insidertransaktion11/5/2025
10-QQuartalsbericht11/4/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/4/2025
144144-Formular11/3/2025
144144-Formular11/3/2025
SCHEDULE 13GSCHEDULE 13G-Formular10/31/2025
4Insidertransaktion10/30/2025
144144-Formular10/28/2025
4Insidertransaktion10/8/2025
4Insidertransaktion9/29/2025
144144-Formular9/25/2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular9/12/2025
4Insidertransaktion9/4/2025
4Insidertransaktion9/4/2025
4Insidertransaktion8/29/2025
4Insidertransaktion8/28/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/27/2025
144144-Formular8/27/2025
424B7424B7-Formular8/27/2025
144144-Formular8/26/2025
4Insidertransaktion8/21/2025
4/A4/A-Formular8/21/2025
4Insidertransaktion8/21/2025
4Insidertransaktion8/21/2025
4Insidertransaktion8/21/2025
4Insidertransaktion8/21/2025
4Insidertransaktion8/21/2025
144144-Formular8/20/2025
144144-Formular8/20/2025
144144-Formular8/20/2025
144144-Formular8/20/2025
144144-Formular8/19/2025

Tempus AI Documents 2026

This page contains all official documents and SEC filings for Tempus AI stock (TEM, ISIN: US88023B1035). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Tempus AI's regulatory filings.

Tempus AI Stock analysis

Tempus AI Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes.